Locally Advanced Gastric Cancer: Neoadjuvant Treatment

Over the years the treatment strategy of gastric cancer (GC) has been modified to improve clinical outcome. Neoadjuvant and perioperative therapies are emerging as the new standard of care in the setting of locally advanced disease, with systemic treatment performed also before surgery. At the same time, the molecular and biological aspects of disease are becoming important factors conditioning the results. Conducted studies confirm the improvement in the long-term prognosis of operable GC with neoadjuvant or perioperative strategy. To date, we have no clear data to identify the best strategy to be used, so it is necessary to design studies that integrate clinical and biological variables for GC to improve knowledge and better define treatment strategies.